GraceL.ChenMDMPH

Infectious Disease • Bethesda, MD

Vice President, Head of Clinical Development, Hillevax

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

Office
Vaccine Research Center, NIAID, NIH
Bethesda, MD 20892
Phone+1 301-646-0725

Education & Training

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 2006 - 2008
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2005
NYU Grossman School of MedicineInternship, Internal Medicine, 2002 - 2003
George Washington University School of Medicine and Health SciencesClass of 2002

Certifications & Licensure

HI State Medical License 2005 - 2026
DC State Medical License 2015 - 2022
VA State Medical License 2012 - 2014
ME State Medical License Active through 2013
NY State Medical License 2005 - 2012

Clinical Trials

Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Start of enrollment: 2015 Nov 18
Completed
Phase 2
Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults Start of enrollment: 2017 Apr 24
Completed
Phase 1
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Start of enrollment: 2017 Mar 29
Completed
Phase 2
Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults Start of enrollment: 2017 Oct 25
Completed
Phase 1
Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults Start of enrollment: 2019 Apr 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

38 citations
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation cli...
Tracy J. Ruckwardt, Kaitlyn M. Morabito, Emily Phung, Michelle C. Crank, Pamela Costner
The Lancet. Respiratory Medicine. 2021-10-01
195 citations
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, Zonghui Hu, Galina Yamshchikov
Lancet. 2017-12-05
79 citations
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults.
Kawsar R. Talaat, Ruth A. Karron, Karen Callahan, Catherine J. Luke, Susan C. DiLorenzo
Vaccine. 2009-06-08

Press Mentions

IAS 2019: First Trial Results of New Immune-Modulating Drugs Presented at Mexico CityJuly 29th, 2019